Xin Lang Cai Jing·2025-08-01 04:12Market Overview - The market experienced a slight decline in early trading, with the three major indices down marginally. The Shanghai and Shenzhen markets had a half-day trading volume of 994.9 billion, a decrease of 147.9 billion compared to the previous trading day. Over 2,900 stocks rose, indicating a mixed performance across the market [1][8]. Sector Performance - The photovoltaic sector saw a collective rebound, with stocks like Jiejia Weichuang hitting the daily limit. The innovative drug sector continued to strengthen, with companies such as Weikang Pharmaceutical also reaching the daily limit. The express logistics sector became active again, with Shentong Express hitting the daily limit. Conversely, the sports sector faced adjustments, with Gongchuang Turf hitting the daily limit [1][3][5]. Individual Stock Highlights - In terms of individual stocks, there were 35 stocks that hit the daily limit (excluding ST and newly listed stocks), with a sealing rate of 70%. The number of stocks with consecutive limit-ups was 11, but the market's height decreased to 3 limit-ups. Notable stocks with consecutive limit-ups included Shengtong Energy and Qizheng Tibetan Medicine [1][9]. Photovoltaic Sector Insights - According to a report from CITIC Securities, the photovoltaic industry is currently facing issues of homogenization and excess capacity, making it a core area for the current "anti-involution" movement. With the industry returning to standardized competition and potential supply-side reforms being implemented, the photovoltaic supply chain is expected to see a reasonable price recovery and profit restoration [3][27]. Express Logistics Sector Developments - On July 29, the State Post Bureau held a meeting with express companies to address issues of "involution" competition and illegal charges in rural areas, promoting high-quality industry development. Recent revisions to the Price Law and the Anti-Unfair Competition Law provide legal support for price stabilization in the industry [5][10]. Innovative Drug Sector Progress - Companies like Haishi Pharmaceutical and Huahai Pharmaceutical announced significant advancements in their innovative drug pipelines, with FDA applications and clinical trial approvals being granted. CITIC Securities noted that the development of innovative drugs in China has achieved significant progress, and supportive measures for high-quality development are expected to further enhance this sector [8][5].